How many years can one survive taking the targeted drug Mobocertinib?

Mobocertinib (Mobocertinib) is a new type of targeted drug, mainly used to treat EGFR (epidermal growth factor receptor) mutant non-small cell lung cancer (NSCLC). EGFRMutantNSCLC is a common subtype of lung cancer that usually involves mutations in the EGFR gene. These mutations make lung cancer cells overly sensitive to the EGFR signaling pathway, promoting their growth and spread. The emergence of moboxetinib provides a new treatment option for these patients, but the survival period after its use needs to be discussed in conjunction with clinical trial data.

Clinical trials are a key means of evaluating the efficacy and safety of new drugs. The efficacy data of mobosetinib mainly come from a study called “EXPERT”(NCT02716116 ) clinical trial, which aims to evaluate the efficacy of mobosetinib in patients with EGFR mutant NSCLC. The following are survival data related to mobosetinib treatment:

1.Overall Survival (Overall Survival, OS): Overall survival refers to the time from the start of treatment to the death of the patient. Overall survival data for mobosetinib in the EXPERT trial are still being studied and may be updated over time. Generally, the overall survival of patients with EGFRmutantNSCLC can be extended, but the specific extent of extension may vary depending on individual differences and other factors.

2.Progression-Free Survival (PFS): Progression-free survival refers to the time from the start of treatment to the progression of the disease. Based on early EXPERT trial data, mobosertinib has the potential to improve EGFR T790Mmutation-positive NSCLC patients demonstrated excellent PFS with a mean PFS exceeding 12 months. This shows that moboxetinib can effectively control the progression of the disease and prolong the stable period of patients.

3.Overall Response Rate (Overall Response Rate, ORR): The overall response rate refers to the proportion of patients’ tumors that shrink or disappear after treatment. According to clinical trial data, mobosetinib showed high ORR in patients with EGFR T790M mutation-positive NSCLC, which means many patients can see significant shrinkage or disappearance of tumors after treatment.

It needs to be emphasized that the survival time of an individual patient may be affected by a variety of factors, including the type of tumor, the type of mutation, the duration of treatment, the patient's overall health, etc. In addition, as a new drug, data on the long-term efficacy of mobosertinib may still be accumulating and more time will be needed to fully evaluate it.

For patients with EGFRmutatedNSCLC, moboxetinib represents an important treatment option that may improve disease control and survival. However, patients should closely follow their doctor's recommendations during treatment and undergo regular monitoring and follow-up visits to ensure optimal treatment results.

In summary, mobosetinib showed promising efficacy in patients with EGFRmutantNSCLC, including prolonged PFS and high ORR. Regarding its impact on overall survival, further research and time are needed to fully evaluate. Treatment results will vary depending on a patient's specific situation, so patients should work closely with their doctor to develop the most appropriate treatment plan.

Mobotinib is currently on the market in China, but it is not included in medical insurance. Patients need to pay for it in full, so the price is very high. Please consult the local hospital pharmacy for specific prices. Other versions include the Hong Kong version of the original drug Mobotinib, which costs around 7,000 to 8,000 yuan. The generic drug of Mobotinib is mainly a Laotian generic drug. The price is about three to four thousand yuan, which is nearly half cheaper than the original drug. The ingredients of the original drug and the generic drug are the same.